[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Ozmosi [@OzmosiHealth](/creator/twitter/OzmosiHealth) on x 2633 followers Created: 2025-07-24 11:32:20 UTC $ALMS Alumis finishes enrolling patients in global LUMUS Phase 2b trial of ESK-001, an advanced oral TYK2 inhibitor for treating Systemic Lupus Erythematosus. More Info: $XBI $IBB $XPH $PPH  XXX engagements  **Related Topics** [$pph](/topic/$pph) [$xph](/topic/$xph) [$ibb](/topic/$ibb) [$xbi](/topic/$xbi) [more info](/topic/more-info) [$alms](/topic/$alms) [Post Link](https://x.com/OzmosiHealth/status/1948345499792322822)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Ozmosi @OzmosiHealth on x 2633 followers
Created: 2025-07-24 11:32:20 UTC
$ALMS Alumis finishes enrolling patients in global LUMUS Phase 2b trial of ESK-001, an advanced oral TYK2 inhibitor for treating Systemic Lupus Erythematosus.
More Info: $XBI $IBB $XPH $PPH
XXX engagements
/post/tweet::1948345499792322822